

New Test Announcement



Autoimmune Testing

Effective 12/12/2016, St. Luke's Laboratory will begin in-house testing for the following autoimmune assays: Anti-Nuclear Antigen (ANA), Double Stranded DNA (dsDNA), Cyclic Citrullinated Peptide IgA/IgG (CCP), and Extractable Nuclear Antigen (ENA Screen). These assays are part of the Autoimmune Disease Testing Algorithm and/or to Connective Tissue Disease Cascade.

These assays can aid in the diagnosis of systemic rheumatic diseases, which include lupus erythematosus (LE), discoid LE, drug-induced LE, mixed connective tissue disease, Sjögren syndrome, scleroderma (systemic sclerosis), CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome, polymyositis/dermatomyositis, and rheumatoid arthritis when used in conjunction with other clinical findings.

Testing algorithms have been developed for [Autoimmune Disease Testing](#) and [Connective Tissue Disease](#).

Positive ENA Screen samples will reflex to an ENAE (Antibody to Extractable Nuclear Antigen Evaluation) that will be sent to Mayo Laboratories for differentiation for the following: Jo-1, RNP, Scl-70, SM, SS-A and SS-B.

For patients who are currently being monitored using dsDNA or ANA, St Luke's will offer a baseline comparison with Mayo Medical Laboratories for a period of 6 months. Please contact St. Luke's Laboratory at X5200 if you have a patient that requires establishing a new baseline with our in house method.

If you have questions, please contact Dr. Kristin Baer, M.D. Immunology Medical Director (218) 249-5208, Amber LaMourea, MT (ASCP), Immunology Technical Specialist (218) 249-5024, or Jennifer Viergutz, Laboratory Operations Manager (218) 249-5724.

New Test Announcement

